Welcome to our dedicated page for SKINVISIBLE news (Ticker: SKVI), a resource for investors and traders seeking the latest updates and insights on SKINVISIBLE stock.
Skinvisible Inc. (OTCQB:SKVI), through its wholly owned subsidiary, Skinvisible Pharmaceuticals, Inc., is a pioneering R&D pharmaceutical company dedicated to developing enhanced, patent-protected dermatology and healthcare products. These products range from treatments for acne and warts to sunscreens, anti-aging solutions, hand sanitizing lotions, pre-surgical preparations, and other medical treatments beyond dermatology. Central to Skinvisible's innovation is its proprietary technology, Invisicare®, which helps extend the duration active ingredients remain on the skin, allowing for controlled release.
The company's primary goal is to license its prescription and over-the-counter products to global markets, targeting international and multi-national pharmaceutical, cosmetic, skincare, and consumer goods companies. These potential licensees seek new products or methods of managing the lifecycle of their existing offerings. More information about the company and its products can be found at www.invisicare.com and www.skinvisible.com.
Skinvisible has recently made significant strides in clinical trials through its licensee, Quoin Pharmaceuticals, Inc. (NASDAQ:QNRX). The trials focus on the innovative formulation QRX003, leveraging Skinvisible's Invisicare® technology to address Netherton Syndrome (NS), a hereditary skin disorder. Preliminary results are promising, suggesting potential regulatory approval that could make QRX003 the first approved treatment for this condition.
In addition to its work on NS, Skinvisible has filed a provisional patent for a transdermal delivery system targeting obesity through the use of CB-1 receptor antagonists and/or GLP-1 receptor agonists. This system represents a groundbreaking method of delivering obesity drugs, emphasizing convenience and reduced side effects compared to traditional oral or injectable therapies.
By consistently advancing its product pipeline and securing strategic partnerships, Skinvisible aims to provide effective, innovative treatments that fill unmet medical needs and improve patient outcomes.
Skinvisible Pharmaceuticals (OTCQB:SKVI) announced the publication of an article in Drug Development & Delivery highlighting its innovative development of transdermal delivery of glucose-controlling agents using its proprietary Invisicare® technology. Key findings include:
1. A GLP-1 active formulation showed 99.6% transdermal delivery over six hours.
2. CB-1 antagonists demonstrated 62% penetration over six hours.
3. Formulations exhibited sustained drug delivery without initial spikes.
The company has filed two provisional patent applications for these formulations. Skinvisible's CEO, Terry Howlett, emphasized the potential of their topical formulations to avoid side effects associated with oral pills and injections while increasing patient compliance. The global obesity drug market is projected to reach $105-144 billion by 2030. Skinvisible is seeking strategic partnerships to bring the first transdermal obesity therapies to market.
Skinvisible Pharmaceuticals announced promising data on their transdermal obesity formulations using Invisicare technology. The studies showed significant penetration rates: 69% for GLP-1 receptor agonists and 62% for CB-1 receptor antagonists over six hours. Invisicare's formulations also demonstrated sustained drug release, with an average of 10% per hour. These findings suggest that Invisicare can avoid the side effects of oral and injectable obesity drugs, enhancing patient compliance. Skinvisible is seeking strategic partnerships to bring these therapies to market, targeting the growing obesity market projected to reach $131 billion by 2028.
Skinvisible has announced promising data on its transdermal delivery system for obesity drugs using Invisicare technology. The company reported significant penetration rates for GLP-1 receptor agonists and CB-1 receptor antagonists, achieving up to 69% and 62% penetration respectively over six hours. The formulations offer sustained drug release, potentially avoiding the side effects of oral pills and injections, and improving patient compliance. The global obesity market is projected to reach $24 billion in 2023 and $131 billion by 2028. Skinvisible is seeking strategic partnerships to commercialize these therapies.
Skinvisible Pharmaceuticals (OTCQB:SKVI) has filed a second patent application for its Invisicare technology, focusing on the transdermal delivery of obesity and glucose-controlling agents. This new application broadens the scope of their initial patent to include additional conditions such as diabetes. The company's Invisicare system maximizes transdermal drug delivery without patches or needles, reducing side effects and enhancing patient compliance. The obesity treatment market is significant, with projections of 30 million GLP-1 users in the USA by 2030, potentially exceeding $100 billion. CEO Terry Howlett highlighted the importance of this development in delivering stable formulations and achieving high transdermal penetration. Skinvisible is also seeking strategic partnerships to further enhance its market impact.
Skinvisible Pharmaceuticals announced the submission of a provisional patent for a new transdermal treatment targeting obesity. This patent leverages the company's proprietary Invisicare technology, which enhances the delivery of CB-1 receptor antagonists and GLP-1 receptor agonists through the skin. The transdermal method aims to offer a more effective and convenient alternative to oral and injectable therapies, potentially improving drug efficacy and reducing side effects. The global obesity drug market is expected to exceed $30 billion by 2027, and Skinvisible aims to capitalize on this by forming strategic partnerships to bring its innovative treatments to market.
Skinvisible, Inc. (OTCQB:SKVI) has announced that its licensee Quoin Pharmaceuticals (NASDAQ:QNRX) received FDA acceptance for an Investigational New Drug (IND) application for QRX003, a treatment for Netherton Syndrome. This marks the first IND approval using Skinvisible's proprietary Invisicare drug delivery technology. Successful clinical trials could lead to a milestone payment of $5 million and ongoing royalties for Skinvisible. The approval underscores the potential for expanding applications of their technology in treating rare skin disorders.
FAQ
What is the current stock price of SKINVISIBLE (SKVI)?
What is the market cap of SKINVISIBLE (SKVI)?
What is Skinvisible Inc.'s primary business?
What is Invisicare®?
What recent projects has Skinvisible Inc. undertaken?
Who are the potential licensees for Skinvisible's products?
What conditions does Skinvisible's product portfolio address?
How does QRX003 formulation benefit Netherton Syndrome patients?
What are the advantages of Skinvisible's transdermal delivery system for obesity drugs?
Where can I find more information about Skinvisible?
What is the market potential for Skinvisible's obesity drug delivery system?
How does Skinvisible ensure the effectiveness of their topical formulations?
